omidubicel

Phase 3Cell therapy

NNational Heart, Lung, and Blood Institute (NHLBI)

omidubicel is one of 43 biologic programs targeting Severe Aplastic Anemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Severe Aplastic AnemiaActive, not recruiting

Hematological MalignanciesCompleted

Severe Aplastic AnemiaPhase 1/Phase 2

Active, not recruiting

Hematological MalignanciesPhase 3

Completed

Competition

Competitive Landscape

77 competitors in Severe Aplastic Anemia

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 3

11 2

Promacta

GSK

Phase 3

7 3

Cytoxan

BBaxter Healthcare Corporation

Phase 3

17 4

Atgam

Novartis

Phase 2

8 5

Cellcept

Roche

Phase 2

3 6

Reblozyl

Bristol-Myers Squibb

Phase 2

2 7

Nplate

Amgen

Phase 2

1 8

Rituxan

Roche

Phase 2

1 9

Hetrombopag Olamine

JJiangsu HengRui Medicine Co., Ltd.

Phase 3

3 10

GVHD Prophylaxis

NNational Cancer Institute (NCI)

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2032

PreclinicalRecruiting

Severe Aplastic Anemia

NCT03173937

Clinical

Trials by Indication[1]

Severe Aplastic Anemia1 trial

Recruiting·NNational Heart, Lung, and Blood Institute (NHLBI)·Preclinical·NCT03173937·37 enrolled

Hematological Malignancies1 trial

An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies

Completed·GGamida Cell ltd·Phase 3·NCT04260698·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for omidubicel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — omidubicel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for omidubicel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Heart, Lung, and Blood Institute (NHLBI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 3[1]
Company: NNational Heart, Lung, and Blood Institute (NHLBI)

omidubicel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2032

Trials by Indication[1]

Severe Aplastic Anemia1 trial

Hematological Malignancies1 trial

References

Drug Info

Quick Facts

Related News